Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

Conditions: Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Abemaciclib; Drug: Anastrozole; Drug: Letrozole
Sponsors: Jonsson Comprehensive Cancer Center; Eli Lilly and Company
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 18, 2026Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments